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Efficacy of galactose and adalimumab in
patients with resistant focal segmental
glomerulosclerosis: report of the font
clinical trial group
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Virginia J. Savin5, Mukut Sharma5, Jochen Reiser6, Changli Wei6, Michael Somers7, Tarak Srivastava8
and Debbie S. Gipson2

Abstract
Background: Patients with resistant focal segmental glomerulosclerosis (FSGS) who are unresponsive to corticosteroids
and other immunosuppressive agents are at very high risk of progression to end stage kidney disease. In the absence of
curative treatment, current therapy centers on renoprotective interventions that reduce proteinuria and fibrosis. The FONT
(Novel Therapies for Resistant FSGS) Phase II clinical trial (NCT00814255, Registration date December 22, 2008) was
designed to assess the efficacy of adalimumab and galactose compared to standard medical therapy which was
comprised of lisinopril, losartan, and atorvastatin.
Methods: Key eligibility criteria were biopsy confirmed primary FSGS or documentation of a causative genetic
mutation, urine protein:creatinine ratio >1.0 g/g, and estimated glomerular filtration rate (eGFR) >40 ml/min/1.73 m2.
The experimental treatments – adalimumab, galactose, standard medical therapy– were administered for 26 weeks.
The primary endpoint was a 50 % reduction in proteinuria with stable eGFR.
Results: Thirty-two subjects were screened and 21 were assigned to one of the three study arms. While none of the
adalimumab-treated subjects achieved the primary outcome, 2 subjects in the galactose and 2 in the standard medical
therapy arm had a 50 % reduction in proteinuria without a decline in eGFR. The proteinuria response did not correlate
with serial changes in the serum glomerular permeability activity measured by the Palb assay or soluble urokinase plasminogen activator receptor (suPAR). There were no serious adverse effects related to treatments in the study.
Conclusions: Recruitment into this trial that addressed patients with resistant FSGS fell short of the enrollment goal.
Our findings suggest that future studies of novel therapies for rare glomerular diseases such as FSGS may benefit from
enrollment of patients earlier in the course of their disease. In addition, better identification of patients who are likely to
respond to a new treatment based on biomarkers suggesting involvement of the disease pathway targeted by the
experimental agent may reduce the required sample size and increase the likelihood of a favorable outcome.
Keywords: FSGS, Galactose, Adalimumab, Renoprotective, Antifibrotic, Permeability factors
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Background
Focal segmental glomerulosclerosis (FSGS) is an important cause of nephrotic syndrome in children and adults
and accounts for a sizable number of patients who develop end stage kidney disease (ESKD) [1]. FSGS can be
primary, genetic, or secondary to a wide range of clinical
conditions including obesity, HIV infection, medications,
or reflux nephropathy [2, 3]. Regardless of the underlying
etiology, podocyte dysfunction and loss are considered the
pivotal events in the pathogenesis of the disease [4].
Current therapy involves administration of corticosteroids
as first-line treatment. Administration of an agent that
blocks the renin-angiotensin-aldosterone axis to lower
proteinuria is standard of care in patients with primary or
secondary FSGS. In those who fail to respond to steroids,
calcineurin inhibitors are the next step in treatment. However, a significant number of patients with FSGS are resistant to corticosteroids and other immunosuppressive
medications [5]. In the recently completed FSGS Clinical
Trial, fewer than half of the patients responded to either
cyclosporine (44 %) or a combination of oral dexamethasone pulses and mycophenolate mofetil (33 %) [6]. Patients who fail to achieve a significant reduction in
proteinuria after treatment with currently available therapeutic options are at high risk of progressing to ESKD
[7, 8]. Moreover, in those who require a kidney transplant,
nearly 25 % manifest recurrent disease in their renal allograft [9]. These findings underscore the pressing need to
develop new treatments for primary idiopathic or genetic
FSGS that are safe and well tolerated.
The FONT (Novel Therapies for Resistant FSGS) study
was a combined Phase I/II clinical trial designed to test new
treatments for patients with refractory FSGS. In the absence
of a defined molecular mechanism of disease, the overall objective was to assess antifibrotic agents that would decrease
proteinuria and reduce glomerular sclerosis progression.
Based on the preclinical and clinical findings implicating the
tumor necrosis factor-α (TNF) and peroxisome proliferator
activator-γ (PPARγ) pathways in FSGS, the trial was originally designed to compare standard conservative therapy
(SCT) versus SCT plus adalimumab versus SCT plus rosiglitazone [10]. Because of patient concerns about potential adverse cardiovascular consequences of rosiglitazone [11], oral
galactose supplementation was substituted for rosiglitazone.
This replacement was made based on pre-clinical and clinical data indicating that galactose neutralizes the activity of a
circulating FSGS permeability factor [12, 13]. This report
summarizes the clinical outcomes of the FONT trial and
highlights difficulties that are encountered in the performance of randomized clinical trials in nephrology.
Methods
The FONT II trial was a Phase I/II open-label RCT designed to select treatments that are worthy of further study
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in randomized Phase III studies. Enrollment into the study
began in July 2009 and was closed in February 2013.
Inclusion and exclusion criteria

The requirements for enrollment into the FONT study
have been described in full detail in a previous report [10].
The key inclusion criteria were: (1) primary FSGS confirmed by renal biopsy or by documented history of a
disease-causing mutation [3]; (2) failure to respond to prior
therapy with corticosteroids and at least one other immunosuppressive medication; (3) age 1–50 years at onset of
proteinuria and 1–51 years at time of randomization; (4) estimated GFR ≥40 mL/min/1.73 m2; (5) Urine protein:creatinine ratio (Up/c) > 1.0 g/g on first morning void and (5) no
immunosuppressive therapy for at least 30 days except low
dose prednisone. Testing for podocyte gene mutations was
not required prior to enrollment in the FONT II trial because renal fibrosis is an intrinsic feature of primary FSGS,
regardless of whether or not there is a defined genetic
mutation.
Screening and run in phase

In this phase, subjects were placed on the maximal tolerated
doses of lisinopril, losartan, and atorvastatin, based on reports of adverse effects and measurements of blood pressure, serum K+, creatinine, liver enzymes, and cholesterol
concentrations. The doses of the angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)
treatment had to be stable for a minimum of 2 weeks prior
to randomization. No specific recommendations were made
regarding daily dietary sodium or protein intake and this
was left to the discretion of the site investigator.
Study medications

All subjects received standard conservative medical therapy
consisting of a combination of the following three agents:
1) lisinopril: 2) losartan; and 3) atorvastatin. The maximum
target doses for subjects weighing <40 kg were: lisinopril
10 mg, losartan 25 mg, and atorvastatin 10 mg. For subjects
weighing >40 kg, the maximal doses were: lisinopril 20 mg,
losartan 50 mg, and atorvastatin 20 mg. The following
novel therapies were administered for 6 months:
Adalimumab (Humira®, TNF antibody)

The dose of adalimumab was 24 mg/m2 (maximum 40 mg/
dose) every other week as a subcutaneous injection for the
entire treatment period. Although the pharmacokinetics
(PK) data from the FONT-I Study indicated enhanced clearance of adalimumab in subjects with FSGS and nephroticrange proteinuria, the dose was not increased above the
standard dosing regimen for other FDA approved indications to minimize the adverse event risk [14].
Galactose (Ferro Pfanstiehl, Waukegan, IL), 0.2 g/kg per
dose was administered orally twice a day, dissolved in 15–
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30 ml of water and ingested 15–30 min before breakfast
and dinner. The maximum single dose was 15 g.
One subject was randomized to rosiglitazone treatment
prior to this arm being dropped and replaced with galactose.
This subject was not included in the analysis. The use of
the full array of experimental therapies in the FONT Phase
II Trial was authorized by the FDA (IND # 100,037).
Primary and secondary outcomes

The co-primary endpoints included:
1. Reduction in proteinuria at 6 months by ≥ 50 % of
the value at the time of screening, AND
2. eGFR at 6 months ≥ 75 % of the value at the time of
randomization in those with an initial eGFR <75 mL/
min/1.73 m2 or eGFR persistently ≥75 mL/min/1.73 m2
in those whose renal function was ≥75 mL/min/
1.73 m2 at the time of randomization
The secondary endpoints were: (1) adverse effect profile;
(2) percent change in proteinuria (evaluated as continuous
variable); (3) change in eGFR, (4) time to halving of eGFR
and ESKD
Study management

Figure 1 outlines the course of the Phase II trial. Subjects
were evaluated after 2, 8, 16, and 26 weeks of the assigned
experimental treatment. A follow-up evaluation was
performed at 1 month, 3 months, and 6 months after
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discontinuation of the novel therapy, and then every
6 months until the end of the funding period. At each
visit, blood was obtained for determination of CBC and a
comprehensive metabolic profile and a first morning urine
sample was obtained for measurement of Up/c. Palb, a
measurement of the capacity of serum to impair the filtration barrier to albumin, was determined at baseline in all
subjects and after 8 and 26 weeks in subjects assigned to
the galactose arm. The serum galactose concentration was
also measured at baseline and after 26 weeks of treatment
in those who were treated with galactose.
Study mandated stop points

Stop points for novel therapy included: 1. >50 % decline
from baseline eGFR and <60 mL/min/1.73 m2 or a final
level <20 mL/min/1.73 m2; 2. ESKD, i.e., initiation of dialysis or receipt of a renal transplant; 3. Serious adverse
event (SAE), i.e. grade 4 CTC toxicity, version 4 (http://
evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-0614_QuickReference_5×7.pdf); 4. Increase in ALT/AST to
>2.5×the upper limit of normal; 5. Onset of congestive
heart failure or a myocardial infarction; 6. Clinical onset of
SLE and/or positive ANA ≥ 1:160; 7. Serious infection including sepsis; 8. Malignancy; and 9. Pregnancy.
Laboratory methods

All routine serum and urine biochemical tests were performed in a central laboratory (Spectra East, Rockleigh, NJ).

Fig. 1 Schematic summary of study design including the various phases of the trial and the three treatment arms
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Galactose was measured in the serum by GC/MS via
modification of a published procedure [15]. In brief, 50 μL
of 100 μg/mL U-13C galactose (Cambridge Isotope Labs)
internal standard prepared in deionized water was added to
200 μL of serum. All other reagents were obtained from
Sigma unless otherwise specified. In order to deplete glucose in the samples, 100 μL 2.5 M potassium bicarbonate,
50 μL 2.5 M phosphate buffer pH 6.5, 25 μL 300 U/μL glucose oxidase in 0.1 M potassium phosphate buffer pH 7
and 25 μL 50U/μL Catalase in 0.05 M phosphate buffer
pH 7, were added and then incubated for 2 h at 37 °C with
mixing. 200 μL each of 0.3 N zinc sulfate and 0.3 N barium
hydroxide were added, the samples were vortexed and left
on ice for 30 min. The samples were centrifuged at
3200 rpm for 10 min.
Prior to derivatization, the sample supernatants were
deionized using cation exchange resin (AG50W-×8 hydrogen form) and anion exchange resin (AG 1-×8, formate
form) (Biorad). Samples were eluted with deionized water
and then dried. Galactose was derivatized to its acetate derivative for GC/MS analysis. 100 μL 20 mg/mL hydroxylamine hydrochloride/pyridine was added to the dried
sample and heated at 70 °C for 30 min. 150 μL acetic anhydride was added with continued heat at 70 °C for another 30 min. The samples were transfer to vials with
inserts for GC/MS analysis.
GC/MS analysis of galactose was done with an Agilent
6890 N Gas Chromatograph equipped with a 7683 Auto
sampler and 5973 Mass Spectrometer and a DB 5 ms capillary column of 40 m × 0.18 mm × 0.18 μm (Agilent Technologies). Helium was used as carrier gas with a constant
flow rate of 1.2 mL/min. Inlet temperature held at 280 °C.
The initial oven temperature held at 180 °C for 30 sec and
temperature ramps 500/min to 2200 hold for 30 sec
followed by 500/min to 300 °C hold for 2 min. 1 μL of derivatized sample was injected in 5:1 split mode.
Mass spectrometer transfer line temperature held at
280 °C and operated in electron impact ionization mode
at 70 eV. Selective Ion Monitoring (SIM) was used for
fragments 314.1 and 319.1, 30 msec dwell time for each.
Galactose concentrations were calculated from relative
peak areas of ions 314.1/319.1.
Palb was determined by the change in glomerular volume after exposure to media with a reduced albumin concentration and oncotic pressure in accord with previously
published methods [16]. Serum suPAR was measured with
the Quantikine Human suPAR Immunoassay (R&D Systems). Podocyte β3 integrin activity was determined by
AP5 immunostaining of differentiated human podocytes
in vitro, accord with previously published method [17].
Statistical methods for analysis of FONT 2 outcome

Continuous data are reported as mean ± SD and in select
instances the median (25, 75 percentile). As noted in the
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study design paper [10], when FONT II was initiated,
the primary analysis of outcome was based on a hybrid
Phase II design [18] with the study conducted in two
phases. The first phase of the study would have ended
when 17 participants had been randomized to each
treatment arm. At that point, a ranking/selection comparison [19, 20] would have been done between the
treatment groups and a minimum rate of success criterion would have been applied to each treatment group.
After that, successful treatments would have moved forward to a second phase of investigation. An experimental therapy in which at least 2 out of the first 17 patients
responded would have been advanced to the full Phase
II assessment. A total of 42 subjects would have been
assigned to each group (15 additional participants would
have been enrolled in the galactose arm to ensure that
42 had a Palb > 0.5). However, because of limited enrollment, the hybrid Phase II design could not be followed.
Instead, the results were analyzed using the FreemanHalton extension of Fisher’s exact test.

Ethics of human subject research

The study protocol, design and consent forms were approved by Institutional Review Board (IRB) at each participating site. This included the Institutional Review Board of
North Shore/LIJ-Cohen Children’s Medical Center, Cincinnati Children’s Medical Center, Boston Children’s Hospital,
Nationwide Children’s Hospital, Doernbecker Children’s
Hospital, Carolinas Medical Center, University of AlbertaStollery Children’s Hospital, Texas Tech University, Children’s Mercy Hospital, University of Kansas, University of
Michigan, Columbia University-College of Physician’s and
Surgeons, NYU School of Medicine-NYU Langone Medical
Center, and University of Miami. Written informed consent
was obtained from all participants or, where participants
were children, from a parent or guardian. Assent was also
obtained from children and adolescents in accord with
guidelines at each site. The trial was authorized by the FDA
under IND number 103,147. It was listed at ClinicalTrials.gov with the identifier NCT00814255 and the registration
date was December 22, 2008.

Results
Subject characteristics

Thirty-two subjects consented and enrolled in the study.
However, only 21 subjects were randomized to one of the
treatment arms (Fig. 2). The reasons that subjects withdrew or were dropped prior to randomization are detailed
in the CONSORT diagram. The duration of the screening
period was 1.8 (1.0, 2.3) (median (25, 75th percentile)
months. Subjects were followed for 1.6 (1.2, 1.7) years
after randomization.
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Fig. 2 CONSORT diagram summarizing the number of subjects who were screened, enrolled, and randomized to the three treatment arms. In
addition, the subject outcomes are provided at the completion of the 6 month Treatment Period and after 6 and 12 months of observation
following the Treatment Period

The demographic and clinical features at baseline of the
subjects who were randomized to one of the experimental
treatments are summarized in Table 1.
Clinical outcomes

The main clinical outcomes for the 21 participants are
summarized in Table 2. When examining change in proteinuria alone, none of the subjects assigned to adalimumab
therapy achieved a 50 % reduction in proteinuria. In contrast, 3 out of 7 subjects assigned to the galactose arm and
2 out of the 7 subjects assigned standard conservative treatment manifested at least a 50 % decline in proteinuria. The
favorable response was sustained for 3–12 months after discontinuation of the galactose but maintenance of all other
treatments. In contrast, the effect of standard conservative
therapy was not sustained after the completion of the treatment period. The primary outcomes, based on the combined proteinuria and eGFR endpoint, are shown in
Table 3. No significant difference in the rates of success was

seen (P = 0.48). The change in Up/c over time in the 5 subjects who had a favorable response to the experimental
treatment is illustrated in Fig. 3. There were no significant
differences in clinical features (age, gender, race) or main
laboratory data (eGFR, Up/c, serum albumin concentration) between the 5 subjects who achieved a 50 % reduction in proteinuria and the 16 other participants who had
persistent proteinuria that was unresponsive to treatment
(Additional file 1: Table S1).

Galactose levels

The serum galactose levels prior to treatment, after
8 weeks, and 26 weeks of galactose treatment were 0.23
± 0.11, 0.68 ± 0.77, and 0.18 ± 0.06 μmol/L, respectively.
These values did not differ from each other (P = 0.10).
The baseline value in 10 subjects who were assigned to
either standard conservative therapy or adalimumab
treatment was 0.31 ± 0.17 μmol/L, which was similar to
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Table 1 Font trial: demographic and clinical features of the subject Cohort
Age at consent

Age at consent

Overall (N = 21)

<18 years (N = 14)

≥18 years (N = 7)

N (%) or Median (IQR)

N (%) or Median (IQR)

N (%) or Median (IQR)

Age at Consent (yr)

14.7 (13.0, 20.8)

13.5 (12.8, 14.7)

28.6 (20.8, 34.0)

Female

12 (57.1 %)

8 (57.1 %)

4 (57.1 %)

Black or African American

4 (19.0 %)

2 (14.3 %)

2 (28.6 %)

White

12 (57.1 %)

7 (50.0 %)

5 (71.4 %)

More than one race

1 (4.8 %)

1 (7.1 %)

Race (self-reported)

Unknown

4 (19.0 %)

4 (28.6 %)

Ethnicity (Self-reported)

7 (33.3 %)

6 (42.9 %)

1 (14.3 %)

Sitting Systolic BP

109 (104, 120)

109 (88.0, 115)

126 (107, 129)

Sitting Diastolic BP

66.0 (60.0, 74.0)

62.5 (54.0, 71.0)

74.0 (68.0, 79.0)

Previous Rx with Cyclosporine

12 (57.1 %)

6 (42.9 %)

6 (85.7 %)

Cyclosporine Rx: Cumulative Exposure (mos)

6.00 (5.50, 12.0)

5.50 (4.00, 12.0)

6.00 (6.00, 12.0)

Previous Rx with Tacrolimus

13 (61.9 %)

8 (57.1 %)

5 (71.4 %)

Tacrolimus Rx: Cumulative Exposure (mos)

7.00 (4.00, 24.0)

9.50 (4.00, 31.0)

6.00 (6.00, 24.0)

Previous Rx with Mycophenolate

11 (52.4 %)

9 (64.3 %)

2 (28.6 %)

Mycophenolate Rx: Cumulative Exposure (mos)

6.00 (4.00, 17.0)

6.00 (5.00, 12.0)

9.50 (1.00, 18.0)

None

14 (66.7 %)

9 (64.3 %)

5 (71.4 %)

Pretibial

6 (28.6 %)

4 (28.6 %)

2 (28.6 %)

Ascites

1 (4.8 %)

1 (7.1 %)

0 (0 %)

Edema

Serum Albumin (g/dL) at Screening

2.40 (2.10, 3.50)

2.40 (2.05, 3.60)

2.50 (2.10, 3.50)

Total Cholesterol (mg/dL) at Screening

276 (198, 424)

297 (163, 452)

267 (198, 424)

Up/c at Screening

4.93 (3.30, 11.5)

9.28 (3.30, 12.2)

3.41 (3.23, 4.93)

Baseline eGFR (ml/min/1.73 m2)

120 (81.1, 170)

119 (88.2, 221)

120 (71.5, 151)

Duration of Follow up Post Randomization (yr)

1.63 (1.27, 1.74)

1.66 (1.48, 2.03)

1.24 (1.06, 1.70)

Note: Excludes the subject randomized to Rosiglitazone

the concentration at baseline in the participants who
were assigned to galactose therapy.
Biomarkers – Palb and suPAR

The Palb, suPAR, and AP5 values at the onset of the
study and after 8 and 26 weeks of galactose treatment
are depicted in Fig. 4. At the time of randomization,
Palb was ≥ 0.5 (normal Palb: <0.2) in all 18 subjects
(8 assigned to the galactose [1 child was withdrawn because of an elevated ANA titer in the baseline sample
after randomization]), 4 to the adalimumab and 6 to
the standard medical treatment arm) in whom the
assay was performed. It declined in all 7 subjects who
received oral galactose treatment and the value was
within the normal range throughout the course of therapy (Fig. 4a). In contrast, the Palb value was unchanged
after the 26-week treatment period in 2 subjects who
received adalimumab and 2 on standard medical

treatment (data not shown). The decline in Palb was
significantly different in the galactose versus the two
treatment groups (P = 0.003). The consistent decline in
Palb in the subjects assigned to galactose was associated
with a 50 % or greater decrease in 3 of 7 subjects (see
above). Plasma suPAR levels were initially elevated
(>3,000 pg/ml) in 8 out of 22 (36 %) subjects who had measurement performed at baseline. There was no consistent
change in circulating suPAR concentration in response to
galactose therapy and no consistent relationship between
suPAR levels and the change in proteinuria over the 26week treatment period (Fig. 4b). Similarly, there was no consistent change in AP5 staining of podocytes incubated with
subject serum during the course of any treatment and this
biomarker did not correlate with the reduction in urinary
protein excretion (Fig. 4c). There was no correlation between Palb and suPAR or AP5 staining in the analyzed
subjects.
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Table 2 Font trial: Clinical outcomes
Participant Up/c
Up/c
% Change Up/c responder
month 0 month 6 Up/c

eGFR
eGFR
eGFR
month 0 month 6 preservation

Primary
Duration (yr) follow-up
outcome met? post randomization

RX = Adalimumab
1

2.1

12.3

475.0

No

325

41

No

No

2.5

2

6.3

6.6

5.0

No

140

155

Yes

No

2.0

3

14.9

8.4

−43.8

No

88

116

Yes

No

1.6

4

4.7

6.1

31.0

No

120

93

Yes

No

1.7

3.4

.

.

Never received
study drug

81

.

Never received
study drug

No

0.1

6

2.3

1.6

−30.5

No

37

29

Yes

No

1.5

7

2.1

5.2

142.5

No

58

24

No

No

1.7

5a,b

RX = Galactose
8

9.0

3.2

−64.5

Yes

71

41

No

No

2.1

9

3.3

0.9

−72.8

Yes

143

129

Yes

Yes

1.7

10

3.3

0.5

−86.0

Yes

97

91

Yes

Yes

1.6

11

12.2

10.8

−11.4

No

91

63

No

No

1.4

12a

49.3

29.9

−39.2

No

63

35

No

No

1.6

13

1.5

1.0

−29.9

No

221

180

Yes

No

1.3

14

6.7

7.0

4.7

No

71

67

Yes

No

1.1

276

283

Yes

No

2.1

c

RX = Standard Therapy (lisinopril, losartan, atorvastatin)
15

4.6

2.8

−40.3

No

16

16.0

5.0

−68.5

Yes

235

180

Yes

Yes

1.5

17a,b

11.6

.

.

Never received
study drug

170

.

Never received
study drug

No

0.0

18

3.2

2.5

−22.7

No

151

108

Yes

No

1.2

19

4.9

2.2

−54.6

Yes

155

150c

Yes

Yes

1.2

20

9.6

5.5

−42.2

No

173

178

Yes

No

1.7

21

11.5

14.2

23.2

No

94

.57c

No

No

1.8

Abbreviations: eGFR, estimated glomerular filtration rate; Up/C urine protein:creatinine ratio 1) Excludes the subject randomized to Rosiglitazone; 2) One
participant in each arm was neither on ACEi, nor ARB a,Participant did not receive neither ACEi, nor ARB; b, Participant did not start assigned trial therapy;
c
Participant had eGFR calculated based on testing performed at a local laboratory

Adverse outcomes

The serious adverse events that occurred during the study
are summarized in Table 4. The other adverse effects are
itemized in Table 5. Although most of the subjects did experience at least one averse event during the treatment
Table 3 Font trial: outcomes by treatment arm
Treatment arm
Outcome

Adalimumab

Galactose

Standard

Total

Success

0

2

2

4

Failure

7

5

5

17

Total

7

7

7

21

The co-primary endpoints included: (1) Reduction in proteinuria at 6 months
by ≥ 50 % of the value at the time of screening, AND (2) Estimated GFR (eGFR)
at 6 months ≥ 75 % of the value at the time of randomization in those with an
initial eGFR <75 mL/min/1.73 m2 OR eGFR persistently ≥75 mL/min/1.73 m2 in
those whose renal function was ≥75 mL/min/1.73 m2 at the time of
randomization

period, these side effects did not necessitate discontinuation
of the assigned experimental treatment.

Discussion
General

The only treatment that satisfied the criterion for success in this limited study of novel therapies for patients
with resistant FSGS was galactose. Oral administration
of this monosaccharide achieved at least a 50 % reduction in proteinuria in 3 out of 7 or 42 % of the treated
subjects, 2 of whom maintained a stable eGFR. It is difficult to interpret the response to galactose therapy in response to the serial measurements of the circulating
level of the sugar. Although there was no significant
change in serum galactose concentration over the course
of the study, this is not unexpected because galactose is
rapidly metabolized to glucose. In addition, the serum
galactose concentration was measured at arbitrary times
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Fig. 3 Time course of the response, assessed by the Up/c in a first morning urine sample, in the 5 subjects who achieved a ≥50 % reduction in
proteinuria in response to the experimental therapy

and we did not standardize blood sampling in relationship to the oral dosing schedule (trough level or fixed
interval after ingesting the monosaccharide). However,
the consistent decrease in Palb in all subjects who received galactose suggests that all of the subjects adhered
to the assigned treatment and is consistent with prior
experience with the sugar [12]. There was no evidence
of adverse effects related to the use of galactose and future studies of this agent may benefit from a stable formulation that is already prepared ready for use. Our
findings are somewhat at variance with the data of
Sgambat et al. [21] who administered galactose to 7
pediatric subjects with steroid-resistant nephrotic syndrome (2 with post-transplant FSGS), none of whom
achieved a reduction in proteinuria despite a fall in Palb.
Differences in age, confirmation of the diagnosis of
FSGS, by renal biopsy, and inclusion of patients with recurrent disease may account for the modest differences
between this negative report and our findings.
It is worth noting that while 0 out of 7 subjects who
were assigned to adalimumab in the FONT trial
achieved a favorable response to treatment, 4 out of 10
subjects who received adalimumab over 16 weeks in
FONT I had at least a 50 % decline in proteinuria [14].
Preliminary data from the NEPTUNE cohort study indicate that there is genomic evidence of TNF activation in
a subset of patients with primary FSGS (unpublished

observations). It is plausible that future efforts to delineate a molecular signature of TNF activation may be useful
in identifying individual patients with FSGS who are more
likely to respond to a TNF antagonist. It is becoming increasingly apparent that primary FSGS is a heterogeneous
disorder with some cases representing a genetic disorder of
the podocyte and others arising from alterations in the integrity of the glomerular barrier due to a circulating factor
(see below). It is anticipated that in the future, improved efforts to characterize patients based on their underlying genetic and molecular profiling will facilitate better selection of
patients who have a greater likelihood of responding to a
targeted therapy. Two out of the 7 subjects who were
assigned to conservative medical therapy also achieved a
50 % reduction in proteinuria, which supports the need to
include this control arm in any prospective trial of a novel
therapeutic agent in patients with resistant FSGS.
There are several features about the FONT study design that are worthy of note. The entry criterion, Up/c >
1, is lower than a cut-off value of 2 used in most studies.
As such, it might appear to be less stringent than the
usual definition of partial response, namely a 50 % decline in proteinuria from an initial value exceeding 2.
The definition used in this trial was an extension of the
entry criterion into the FSGS Clinical trial [6]. In fact,
the mean Up/c was 4.9 and exceeded 2 in all cases.
Moreover, using a cut-off of Up/c > 2 did not alter the
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Fig. 4 Serial changes at baseline, week 8, and week 26 in the subjects who were assigned the galactose treatment for (a) Palb; (b) suPAR; and (c)
AP5. Each line represents a single subject

results. The study was open label because of a reluctance to implement sham injections in children. However, because the primary outcome involved objective
laboratory measurements, it is unlikely that this influenced the outcomes of the trial.

Permeability biomarkers - Palb and suPAR concentration

Our data suggest that the permeability factors that are
defined by the Palb bioassay [22] and the currently available suPAR ELISA kits are distinct entities [17, 23].
While Palb decreased with galactose administration in

Table 4 Font trial: serious adverse events
Event

Adalimumab (N = 7)

Galactose (N = 7)

Standard Therapy (N = 7)

N PTs
% Rand N
N PTs
% Rand PTs N
N PTs
% Rand PTs N
with events PTs
Events with events
events with events
events
Fatal

0

0

0

0

0

0

0

0

0

Immediate Life Threatening

0

0

0

0

0

0

0

0

0

Required Hospitalization

3

42.9

32

1

14.3

9

1

14.3

1

Prolonged Existing Hospitalization

0

0

0

0

0

0

0

0

0

Persistent or Significant Disability/Incapacity 0

0

0

1

14.3

1

0

0

0

Congenital Anomaly / Birth Defect

1

14.3

1

1

14.3

1

0

0

0

Causes Cancer

0

0

0

0

0

0

0

0

0

Overdose of Study Medication

0

0

0

0

0

0

0

0

0

This Table summarizes the serious adverse events that occurred throughout the study period from screening through to the end of the 6 month observation
period after the completion of the experimental therapy
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Table 5 Font trial: adverse events
Symptom
category

Adalmumab (N = 7)

Galactose (N = 7)

Standard Therapy (N = 7)

N PTs
with events

% of Rand
PTs

N events

N PTs
with events

% of Rand
PTs

N events

N PTs
with events

% of Rand PTs

N events

Allergy

1

14.3

1

2

28.6

2

1

14.3

1

Anorexia

2

28.6

4

1

14.3

1

0

0

0

CV

0

0

0

1

14.3

1

0

0

0

Cataract

0

0

0

1

14.3

1

0

0

0

Cosmetic

0

0

0

0

0

0

1

14.3

2

Cough

3

42.9

3

2

28.6

3

1

14.3

1

Dehydration

2

28.6

5

1

14.3

5

0

0

0

Dizziness

0

0

0

4

57.1

6

1

14.3

1

Edema

6

85.7

100

5

71.4

57

6

85.7

23

Fatigue

5

71.4

8

2

28.6

5

1

14.3

1

GI

4

57.1

7

2

28.6

6

1

14.3

2

Headache

4

57.1

6

4

57.1

8

1

14.3

1

Hypotension

1

14.3

4

0

0

0

0

0

0

Infection

5

71.4

49

5

71.4

20

4

57.1

10

Miscellaneous

4

57.1

13

4

57.1

7

4

57.1

13

Musculoskeletal

3

42.9

8

1

14.3

2

4

57.1

8

Nausea

2

28.6

2

2

28.6

12

0

0

0

Pain

2

28.6

9

4

57.1

14

3

42.9

3

Renal

2

28.6

8

1

14.3

4

1

14.3

1

Respiratory

1

14.3

2

2

28.6

2

2

28.6

2

Skin

2

28.6

3

3

42.9

14

3

42.9

8

Vomiting

2

28.6

5

2

28.6

5

0

0

0

Number of Participants with Adverse Events Reported Overall After Consent

every subject after 8 weeks, suPAR levels were unchanged throughout the cohort regardless of treatment.
In the analyzed samples, there was no correlation between these two potential biomarkers or between either
marker and the proteinuria response. Moreover, neither
measurement in isolation fully accounted for the persistence or decline in proteinuria in this study. This
finding is in contrast to earlier studies which suggested
that elevated suPAR levels may be a biomarker for
primary FSGS [17, 23]. Recent data suggest that full
length suPAR may cause proteinuria in the presence of
specific antibodies, e.g. auto-antibodies against CD40, in
patients who develop recurrent FSGS after receiving a
kidney transplant [24]. A similar 2-hit process may be
involved in the pathogenesis of proteinuria in response
to other putative circulating factors. We urge caution in
interpreting our data about Palb and suPAR in this study
because of the limited sample size and the collection of
samples fairly late during the course of disease in these
subjects with refractory FSGS. Further prospective studies
are needed involving patients with all types of glomerular
disease including FSGS to determine the prognostic

implications of these circulating factors and their role in
the pathogenesis of proteinuria and kidney injury.
Problems with Clinical Trials in FSGS

It is recognized that nephrology ranks near the bottom
among medical specialties in the performance and completion of clinical trials [25, 26]. Enrollment into the
FSGS Clinical Trial that served as the antecedent to the
FONT Trial was below expectations [27]. Poor subject
comprehension of the adverse consequences of CKD,
the adverse effects of many proposed treatments, and
the high incidence of rapid decline in kidney function in
patients with refractory proteinuria are among the explanations that have been offered to account for low enrollment into nephrology studies and specifically trials of
glomerular diseases. It is likely that all of these factors
contributed to the low recruitment into the FONT trial.
Problems with subject recruitment underscore the need
to create an infrastructure for clinical research and to
design pragmatic trials that can be implemented in a
timely manner to test potential treatments in patients
with rare diseases like FSGS.
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Two additional and specific factors may have played a
role in limiting recruitment into the FONT Trial. First, by
restricting the enrollment to patients who had failed steroids and at least one other immunosuppressive medication, we preselected for those with established disease of
several years duration. These patients may be at very high
risk of rapid deterioration in kidney function compared to
patients evaluated soon after the onset of the disease. In
fact, several of the treatment resistant subjects who were
offered participation in the study experienced a rapid decline in GFR during the screening period and became ineligible. These observations suggest that it may be
prudent to consider clinical trials of novel therapies earlier
in the course of glomerular disease with persistent proteinuria. Such patients may have more reversible anatomic
changes to glomeruli and the interstitium and their renal
function may be more likely to remain stable during the
course of the screening evaluation and experimental treatment period. Second, this trial transpired during a period
when rosiglitazone and adalimumab were each receiving
intense scrutiny because of reports of serious adverse
events. Specifically, the FONT trial study was launched almost simultaneously with the publication of a metaanalysis that suggested that rosiglitazone increased the risk
of cardiovascular complications in adults receiving the
drug for the management of type 2 diabetes [11]. Although the FDA never questioned the rationale for testing
thiazolidinediones in patients with resistant FSGS, the ongoing adverse publicity surrounding the use of PPAR-γ agonists dampened patient willingness to be randomized to
that arm. As a consequence, we replaced rosiglitazone
with galactose, a test agent with no known adverse effects.
In addition, a report appeared at nearly the same time
linking the adalimumab to the occurrence of serious infections and malignancy [28]. This diminished physician enthusiasm for adalimumab as a treatment arm in FONT
even though the adverse consequences of adalimumab
were documented in patients who receiving adalimumab
in conjunction with other immunosuppressive drugs as
treatment for rheumatological diseases. A follow-up report substantially downgraded the level of risk associated
with adalimumab [29]. Finally, it is unclear what impact
subject perception of a randomization scheme that compared an oral treatment thought to have minimal risk (galactose) to an injectable drug with a well-defined risk
profile had on enrollment. Some potential participants
expressed concern about a perceived imbalance in risk between the study arms and voiced a strong preference for
galactose. They may have declined to participate in the
trial without assurance that galactose was the test therapy
they would receive. These observations remind us that
clinical trials occur in a real world context and enrollment
can be seriously impacted by a wide range of extraneous
factors, some that are beyond the control of the
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investigative team and others that can be addressed during protocol development.

Conclusion
The FONT Trial provides data that must be considered as
hypothesis generating rather than hypothesis testing due
to the small sample size. Our findings suggest that adalimumab is not a viable agent for further study in patients
with resistant FSGS. However, taking into account the
combined results of the Phase I (4 out of 10 subjects had
a 50 % reduction in proteinuria in response to a 16-week
course of treatment [14]) and Phase II studies of adalimumab, additional investigation may be warranted to determine if a subgroup of subjects with TNF associated
disease can be identified who would benefit from treatment with inhibitors of the cytokine. Galactose also appears to be of potential value because of proteinuria
reduction and preservation of kidney function in some
subjects as well as its ease of administration and excellent
side effect profile. However, future testing will be necessary and may be strengthened by better delineation of the
relationship between Palb and fibrosis and enrollment of
patients with earlier disease. Implementation of alternative
study designs such as adaptive clinical trials or “n-of-1”
trials may be useful to assess response to novel treatments
in patients with rare conditions such as FSGS [30, 31]. It
is not justified to proceed to a formal Phase II or III trial
of either adalimumab or galactose in a non-selected cohort of patients with resistant FSGS based on the findings
of the FONT study. The results add to the body of evidence that suggests that future trials of novel agents in
FSGS will benefit from a selected cohort approach where
patients with a particular mechanism of disease are enrolled into trials of agents that are directed to the active
target. The inclusion of a control or standard therapy arm
remains mandatory. FSGS includes a constellation of diseases categorized by common pathology features. Standard therapies have approached these diseases as a single
entity with the trialing of a series of therapies until a response occurs or futility is reached following multiple
drug failures. This FONT trial launched with Phase I in
2008 and Phase II in 2009 and was designed to test novel
therapies in individuals with multi-drug resistance. While
these treatment resistant patients assuredly need better
therapies, a contemporary approach based on molecular
profiling of an individual patient may improve the selection of initial target-based therapy. Benefits of a targeted
approach may also minimize the cumulative drug related
toxicities that accompany sequential therapies observed in
these patients. Making the transition to precision medicine will require partnership with patients, clinicians, investigators, and the pharmaceutical and biotechnology
industries for target identification, trial design, early phase
drug development and drug testing. Finally, a greater
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willingness on the part of clinicians and patients will be
required to engage in the process of discarding drugs with
poor risk-benefit profiles while testing promising agents
early in the disease course.

Additional file

Page 12 of 13

2.
3.

4.
5.

Additional file 1: Table S1. Font trial: comparison of proteinuria
responder versus resistant subjects.
Abbreviations
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor
blocker; CKD: Chronic kidney disease; ESKD: End stage kidney disease;
FONT: Novel Therapies for Resistant FSGS; FSGS: Focal segmental
glomerulosclerosis; GFR: Glomerular filtration rate; IRB: Institutional review
board; PK: Pharmacokinetic; SAE: Serious adverse event; SCT: Standard
conservative therapy; TNF: Tumor necrosis factor-α; Up/c: Urine
protein:creatinine ratio.

6.

7.

8.

9.
10.

Competing interests
Jochen Reiser is a cofounder of TRISAQ, a biopharmaceutical company
aimed to develop novel kidney protective therapies. He stands to gain
royalties from present and future commercialization. None of the other
authors have any competing interests related to the work described in this
report. The views expressed in this article are those of the authors and do
not necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States Government.
Authors’ contributions
HT, DSG, and JG developed the study design. HT, DSG, MR, JG participated in
the analysis and interpretation of data. HT, DSG, SV, EH, MS (MD), and TS
monitored patient enrollment and quality assurance during the tral. HT, DSG,
SV, EH, MR assisted in the collection of data. DTS, MS (PhD), VJS, CW, and JR,
performed specific laboratory tests related to the study. HT, DSG, SV, EH, MR,
JG, MS (MD), TS, and VJS participated in drafting the manuscript. All authors
reviewed and approved the final version of the manuscript.

11.

12.

13.

14.

15.

16.
Acknowledgements
This study was supported by funding from the National Institutes of
Health—National Institute of Diabetes, Digestive, and Kidney Diseases, grant
DK70341 (HT). The authors express their appreciation to all of the subjects who
chose to participate in the FONT trial and the study coordinators who helped take
care of the participants in a comprehensive manner. Part of the study was
performed at the KCVA Medical Center, Kansas City, MO, Department of Veterans
Affairs, Veterans Health Administration. The authors thank Abbott Laboratories for
providing the adalimumab for use in the project. They acknowledge the support
of NephCure Kidney International that enabled performance of several of the
study related tests (Palb measurements). Galactose was measured in the Biomarker
Analytical Research Core Laboratory of the Einstein Institute for Clinical and
Translational Research supported by grant 1UL1TR001073-02
Author details
NYU Langone Medical Center, CTSI, Room #110, 227 E 30th Street, New
York, NY, USA. 2University of Michigan, Ann Arbor, MI, USA. 3Cleveland Clinic
Foundation, Cleveland, OH, USA. 4Albert Einstein College of Medicine, Bronx,
NY, USA. 5Kansas City Veteran’s Administration Medical Center, Kansas City,
MO, USA. 6Rush University Medical Center, Chicago, IL, USA. 7Boston
Children’s Medical Center, Boston, MA, USA. 8Children’s Mercy Hospital,
Kansas City, MO, USA.
1

17.

18.
19.
20.
21.

22.

23.

24.

Received: 6 February 2015 Accepted: 24 June 2015
25.
References
1. Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and
chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis.
2011;18(5):332–8.

26.

Fogo AB: Causes and pathogenesis of focal segmental glomerulosclerosis. Nat
Rev Nephrol 2014 Dec 2. doi:10.1038/nrneph.2014.216. [Epub ahead of print]
Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al; the SRNS
Study Group, Hildebrandt F: A single-gene cause in 29.5 % of cases of
steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2014 Oct 27. pii:
ASN.2014050489. [Epub ahead of print]
Schell C, Huber TB. New players in the pathogenesis of focal segmental
glomerulosclerosis. Nephrol Dial Transplant. 2012;27(9):3406–12.
Sethna CB, Gipson DS. Treatment of FSGS in Children. Adv Chronic Kidney
Dis. 2014;21(2):194–9.
Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ,
et al. Clinical trial of focal segmental glomerulosclerosis in children and
young adults. Kidney Int. 2011;80(8):868–78.
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis
Registry Group. Focal and segmental glomerulosclerosis: definition and relevance
of a partial remission. J Am Soc Nephrol. 2005;16(4):1061–8.
Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al.
Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol.
2006;21(3):344–9.
Leca N. Focal segmental glomerulosclerosis recurrence in the renal allograft.
Adv Chronic Kidney Dis. 2014;21(5):448–52.
Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, et al. Novel
therapies for resistant focal segmental glomerulosclerosis (FONT) phase II
clinical trial: study design. BMC Nephrol. 2011;12:8. doi:10.1186/1471-2369-12-8.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med.
2007;356(24):2457–71.
Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to
focal segmental glomerulosclerosis permeability factor and inhibits its
activity. Transl Res. 2008;151(6):288–92. doi:10.1016/j.trsl.2008.04.001.
De Smet E, Rioux JP, Ammann H, Déziel C, Quérin S. FSGS permeability
factor-associated nephrotic syndrome: remission after oral galactose
therapy. Nephrol Dial Transplant. 2009;24(9):2938–40.
Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase
1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II.
Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J
Kidney Dis. 2010;55(1):50–60.
Schadewaldt P, Hammen HW, Loganathan K, Bodner-Leidecker A, Wendel
U. Analysis of concentration and 13C Enrichment of D-Galactose in human
plasma. Clin Chem. 2000;46(5):612–9.
Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin
reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol.
1992;3:1260–9.
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating
urokinase receptor as a cause of focal segmental glomerulosclerosis.
Nat Med. 2011;17(8):952–60.
Liu P, John C, Marcel D. Phase II Selection Designs, Handbook of Statistics in
Clinical Oncology. Chapter 6th ed. 2001. p. 119–27.
Simon R, Wittes R. Ellenberg: Randomized phase II clinical trials. Cancer
Treatment Rep. 1985;69:1375–81.
Buyse M. Randomized designs for early trials of new cancer treatments – An
overview. Drug Inform J. 2000;34:387–96.
Sgambat K, Banks M, Moudgil A. Effect of galactose on glomerular
permeability and proteinuria in steroid-resistant nephrotic syndrome.
Pediatr Nephrol. 2013;28(11):2131–5.
McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in
idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.
Clin J Am Soc Nephrol. 2010;5(11):2115–21.
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al.
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol.
2012;23(12)):2051–9.
Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, et al. A circulating
antibody panel for pretransplant prediction of FSGS recurrence after kidney
transplantation. Sci Transl Med. 2014;6(256):256ra–136. doi:10.1126/
scitranslmed.3008538.
Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of
randomized controlled trials in nephrology. J Am Soc Nephrol.
2004;15(2):411–9.
Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, et al. The
landscape of clinical trials in nephrology: a systematic review of
Clinicaltrials.gov. Am J Kidney Dis. 2014;63(5):771–80.

Trachtman et al. BMC Nephrology (2015)16:111

Page 13 of 13

27. Ferris M, Norwood V, Radeva M, Gassman JJ, Al-Uzri A, Askenazi D, et al.
Patient recruitment into a multicenter randomized clinical trial for kidney
disease: report of the focal segmental glomerulosclerosis clinical trial
(FSGS CT). Clin Transl Sci. 2013;6(1):13–20.
28. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF
antibody therapy in rheumatoid arthritis and the risk of serious infections and
malignancies: systematic review and meta-analysis of rare harmful effects in
randomized controlled trials. JAMA. 2006;295(19):2275–85.
29. Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of
mortality, fatal infection, and fatal malignancy related to use of anti-tumor
necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis
Rheum. 2012;42(3):223–33.
30. Chow SC. Adaptive clinical trial design. Ann Rev Med. 2014;65:405–15.
31. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic
clinical decision methodology for patient-centered comparative
effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S21–8.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

